Answers are grounded in this paper and cite their sources.
Finds long-lasting improvement in working memory with dopamine D1 stimulation in monkeys, suggesting a new treatment for schizophrenia.
Chronic blockade of dopamine D2 receptors, a common mechanism of action for antipsychotic drugs, down-regulates D1 receptors in the prefrontal cortex and, as shown here, produces severe impairments in working memory. These deficits were reversed in monkeys by short-term coadministration of a D1 agonist, ABT 431, and this improvement was sustained for more than a year after cessation of D1 treatment. These findings indicate that pharmacological modulation of the D1 signaling pathway can produce long-lasting changes in functional circuits underlying working memory. Resetting this pathway by brief exposure to the agonist may provide a valuable strategy for therapeutic intervention in schizophrenia and other dopamine dysfunctional states.
No takes yet. Share an insight, caveat, or question.
Castner et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: